20cm速递|科创创新药ETF国泰（589720）盘中涨超2.1%，创新主线或迎来催化

Core Insights - The article highlights a significant increase in the performance of the Guotai Innovation Drug ETF (589720), which rose over 2.1% on October 21, indicating a positive market sentiment towards innovative drug stocks [1] - Huafu Securities suggests that the innovative drug sector has undergone sufficient adjustment since August, and October is seen as a crucial time for investment, particularly in high-quality innovative drug leaders with strong execution capabilities [1] - The article emphasizes the importance of focusing on innovative drugs, medical devices, and companies with improving performance, particularly those with commercial capabilities and rich pipelines in the BioPharma sector [1] Performance Metrics - The Guotai Innovation Drug ETF tracks 30 representative companies in the Shanghai Stock Exchange Science and Technology Innovation Board, primarily focusing on high-growth biotech firms [1] - Since the "924 market" period, the Science and Technology Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovation Drug Index, with respective gains of 117.04% and 109.62% from September 24, 2024, to September 30, 2025 [1] - The article suggests that the Science and Technology Innovation Drug Index may provide better exposure to the resilience of the Science and Technology Innovation Board during periods of market risk appetite recovery [1]